• Latest news

Johnson & Johnson proposes up to $5.5 billion settlement over baby powder cancer lawsuits

July 28, 2026  13:49

Johnson & Johnson (J&J) has proposed paying up to $5.5 billion to settle approximately 76,000 lawsuits in the United States alleging that its talc-based baby powder and other talc-containing products caused ovarian cancer.

The proposed agreement is intended to bring an end to one of the company's longest-running legal disputes. According to J&J, the settlement would cover most of the remaining claims related to its talc products. The company plans to pay up to $3 billion next year, while additional payments would not be due before 2028.

The settlement will only take effect if law firms representing 95% of the ovarian cancer claims in state and federal courts approve the proposal.

Despite offering the settlement, J&J continues to deny any wrongdoing. Erik Haas, the company's vice president of litigation, described the allegations as "without merit," saying the company remains confident it would ultimately prevail in court. However, he said the proposed agreement would allow J&J to put the litigation behind it and focus on developing medicines and medical technologies.

The lawsuits, first filed in 2009, claim that the company's talc products were contaminated with asbestos, a known carcinogen, and that this contamination led to ovarian cancer. Talc is a naturally occurring mineral often mined near asbestos deposits, raising concerns about possible contamination.

Earlier this month, J&J secured a favorable federal court ruling that questioned whether individual plaintiffs could prove talc was the direct cause of their ovarian cancer.

The company maintains that extensive scientific research has shown its talc products are safe, free of asbestos, and do not cause cancer.

J&J stopped selling talc-based baby powder in the United States in 2020 and discontinued the product worldwide in 2022, replacing it with a cornstarch-based formula. Outside North America, legal responsibility for the product now belongs to Kenvue, the former consumer health division that was separated from J&J in 2022.

Follow NEWS.am Medicine on Facebook and Twitter


 
  • Video
 
 
  • Event calendar
 
 
  • Archive